SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is facing intense volatility as traders react to the cyclical nature of its heavy concentration in South Korean semiconductor giants like Samsung and SK Hynix. The community is actively debating whether the stock's recent aggressive price swings represent a sustainable bull cycle fueled by AI-driven memory chip shortages or a risky, over-leveraged trade prone to rapid technical corrections.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently under pressure following media reports that it may be exploring a significant equity raise to support its massive AI infrastructure and data center capital expenditure requirements. Investors are debating whether this potential dilution signifies a long-term strategic commitment to AI dominance or a sign of unsustainable spending, leaving the stock caught between concerns over shareholder impact and its core advertising business performance.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

The ProShares Bitcoin Strategy ETF is trending as investors grapple with its ongoing price volatility alongside broader market fluctuations in Bitcoin. Community discussion is heavily focused on the contrast between the ETF's consistent monthly dividend payouts and the NAV decay, with many debating whether to hold for income or shift into spot Bitcoin products.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing extreme downward pressure, with community members expressing panic and frustration as the token hits multi-year lows. Many investors are debating whether these levels represent a rare buying opportunity or a signal of deeper structural failure, with sentiment largely split between those aggressively averaging down and those who believe the crypto sector is facing a terminal decline.

TON (The Open Network) is a general-purpose&nbsp;blockchain that allows developers to build decentralized apps and tokens.

Toncoin

Toncoin is attracting significant community attention as investors weigh the impact of its deep integration with the Telegram ecosystem against recent market volatility and technical resistance. While some traders are focused on the growth of Ton-based wallet activity and new institutional listings, others are debating the sustainability of current price levels amid ongoing concerns regarding token unlocks and structural market shifts.

Leidos Holdings, Inc. engages in providing services and solutions in the defense, intelligence, civil and health markets. It operates through the following three segments: Defense Solutions, Civil, and Health. The Defense Solutions segment provides services, solutions, and products focusing on digital modernization, mission systems and integration, command, control, computers, communications, intelligence, surveillance and reconnaissance technologies and services, maritime solutions, transformative software, analytics, intelligence analysis, mission support and logistics services, weapons systems and space systems and solutions. The Civil segment focuses on modernizing infrastructure, systems, and security. The Health segment offers solutions to federal and commercial customers that are responsible for the health and wellbeing of people worldwide including service members and veterans. The company was founded by John Robert Beyster on February 3, 1969 and is headquartered in Reston, VA.

Leidos Holdings Inc

Leidos Holdings is currently in the spotlight as investors track its strong performance across defense and digital modernization, underscored by a steady stream of high-value government contracts. The community is actively debating its valuation compared to peers and focusing on the company's expanding footprint in AI-driven security and defense infrastructure.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is experiencing significant market volatility as investors focus on the promising data from its late-stage study on paridiprubart for acute kidney injury. Community discussion is heavily divided between those anticipating a major partnership or acquisition based on the drug's potential and skeptics warning of potential dilution or management's historical lack of clear communication.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is seeing heightened volatility and community debate as investors speculate on potential squeeze dynamics similar to other rental car sector movements, further fueled by news of its partnership with Uber for autonomous fleet services. Traders are closely monitoring the stock's consolidation patterns, significant short interest, and upcoming earnings for signs of a long-term turnaround.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is experiencing intense investor interest as the April 30th PDUFA date for the Auvelity label expansion into Alzheimer's agitation approaches, with analysts increasingly confident in an approval. Community sentiment remains bullish, highlighting the drug's potential as a first-in-class treatment for an underserved market and viewing recent stock volatility as a buying opportunity ahead of anticipated regulatory success and upcoming earnings.

Solidion Technology, Inc. engages in researching, developing and manufacturing battery components and materials, batteries and related energy storage products for the automotive electric vehicle and other markets. The company was founded on June 30, 2023 and is headquartered in Dallas, TX.

Solidion Technology Inc

Solidion Technology Inc. is seeing intense investor interest driven by back-to-back announcements regarding proprietary lithium-metal battery patents, which are being linked by the community to high-growth themes like space infrastructure, SpaceX's upcoming IPO, and AI-driven energy needs. While bullish sentiment focuses on extreme short-squeeze potential and a low float, others are debating whether the rapid valuation jump is backed by fundamental commercial progress or speculative hype.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atrium Therapeutics Reports First Quarter 2026 Financial Results

Atrium Therapeutics Reports First Quarter 2026 Financial Results Atrium Therapeutics Reports First Quarter 2026 Financial Results PR Newswire SAN DIEGO, May 14, 2026 SAN DIEGO, May 14, 2026...

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers...

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, April...

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies Atrium Therapeutics Launches with Approximately $270 Million to Advance...

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Avidity Biosciences Announces Multiple Upcoming...

Promising Medical Stocks To Follow Today - February 26th

Eli Lilly and Company, UnitedHealth Group, Arcellx, Avidity Biosciences, and Novo Nordisk A/S are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks...

Promising Pharmaceutical Stocks To Follow Now - February 26th

Eli Lilly and Company, Avidity Biosciences, Novo Nordisk A/S, AbbVie, Gilead Sciences, Abbott Laboratories, and Pfizer are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...

Avidity Biosciences (NASDAQ:RNA) Issues Quarterly Earnings Results

Avidity Biosciences (NASDAQ:RNA - Get Free Report) released its earnings results on Monday. The biotechnology company reported ($1.59) earnings per share for the quarter, missing analysts' consensus...

Avidity Biosciences, Inc. $RNA Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. grew its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 42.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC...

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders PR...

Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. Its products pipeline includes two lead development candidates: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both conditions are severe, life-threatening, rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. The company was founded on September 30, 2025 and is headquartered in San Diego, CA.

RNAAtrium Therapeutics Inc.

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest RNA News